EA201992690A1 - Применение вибегрона для лечения гиперактивного мочевого пузыря - Google Patents

Применение вибегрона для лечения гиперактивного мочевого пузыря

Info

Publication number
EA201992690A1
EA201992690A1 EA201992690A EA201992690A EA201992690A1 EA 201992690 A1 EA201992690 A1 EA 201992690A1 EA 201992690 A EA201992690 A EA 201992690A EA 201992690 A EA201992690 A EA 201992690A EA 201992690 A1 EA201992690 A1 EA 201992690A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vibegron
treatment
application
hyperactive bladder
relates
Prior art date
Application number
EA201992690A
Other languages
English (en)
Inventor
Стивен К. Писителли
Пол Мадд
Original Assignee
Юровэнт Саенсис Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юровэнт Саенсис Гмбх filed Critical Юровэнт Саенсис Гмбх
Priority claimed from PCT/IB2018/054069 external-priority patent/WO2018224989A1/en
Publication of EA201992690A1 publication Critical patent/EA201992690A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к способу лечения гиперактивного мочевого пузыря, включающему пероральное введение субъекту, нуждающемуся в этом, вибегрона в количестве от приблизительно 60 до приблизительно 90 мг (например, приблизительно 75 мг) в сутки. Настоящее изобретение также относится к фармацевтической композиции в виде единичной лекарственной формы, содержащей от приблизительно 60 до приблизительно 90 мг (например, приблизительно 75 мг) вибегрона для перорального введения.
EA201992690A 2018-03-02 2018-06-06 Применение вибегрона для лечения гиперактивного мочевого пузыря EA201992690A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862637961P 2018-03-02 2018-03-02
PCT/IB2018/054069 WO2018224989A1 (en) 2017-06-06 2018-06-06 Use of vibegron to treat overactive bladder

Publications (1)

Publication Number Publication Date
EA201992690A1 true EA201992690A1 (ru) 2020-05-14

Family

ID=70847666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992690A EA201992690A1 (ru) 2018-03-02 2018-06-06 Применение вибегрона для лечения гиперактивного мочевого пузыря

Country Status (1)

Country Link
EA (1) EA201992690A1 (ru)

Similar Documents

Publication Publication Date Title
MX2020007092A (es) Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos.
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2021004431A (es) Procesos novedosos.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
PH12020550341A1 (en) Niraparib formulations
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA202192199A1 (ru) Композиции, содержащие коричную кислоту, и способы их применения
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
EA202191063A1 (ru) Новая дозированная форма
EA201992690A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
BR112018068784A2 (pt) método para o tratamento de leucemia
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
RU2013126798A (ru) Комбинированная терапия дексаметазоном
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.